CO6450655A2 - Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso - Google Patents
Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de usoInfo
- Publication number
- CO6450655A2 CO6450655A2 CO11140750A CO11140750A CO6450655A2 CO 6450655 A2 CO6450655 A2 CO 6450655A2 CO 11140750 A CO11140750 A CO 11140750A CO 11140750 A CO11140750 A CO 11140750A CO 6450655 A2 CO6450655 A2 CO 6450655A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- quinazolinona
- atropisomeros
- purinil
- tolil
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención provee compuestos, composiciones y métodos de tratar ciertas enfermedades inflamatorias y/o trastornos oncológicos, administrando un compuesto que inhibe isoformas PD K, particularmente la isoforma delta. Provee asimismo estereoisómeros específicos de un compuesto útil para estos métodos. En particular, el compuesto es un atropisómero ópticamente activo de 2-((6-amino-9H-purin-9-iI)metil)-5-metil-3-o-tolilquinazolin-4(3H)-ona.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16298009P | 2009-03-24 | 2009-03-24 | |
US23155009P | 2009-08-05 | 2009-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6450655A2 true CO6450655A2 (es) | 2012-05-31 |
Family
ID=42289320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11140750A CO6450655A2 (es) | 2009-03-24 | 2011-10-20 | Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso |
Country Status (19)
Country | Link |
---|---|
US (1) | US8440677B2 (es) |
EP (1) | EP2411391A1 (es) |
JP (1) | JP2012521994A (es) |
KR (1) | KR20120002995A (es) |
CN (1) | CN102439012A (es) |
AP (1) | AP2011005943A0 (es) |
AU (1) | AU2010229968A1 (es) |
BR (1) | BRPI1012333A2 (es) |
CA (1) | CA2756347A1 (es) |
CL (1) | CL2011002359A1 (es) |
CO (1) | CO6450655A2 (es) |
EA (1) | EA019499B1 (es) |
EC (1) | ECSP11011412A (es) |
IL (1) | IL215251A0 (es) |
MX (1) | MX2011009955A (es) |
NZ (1) | NZ595307A (es) |
PE (1) | PE20120602A1 (es) |
SG (1) | SG174529A1 (es) |
WO (1) | WO2010111432A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
CN101031569B (zh) * | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
AU2009313878B2 (en) | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
US8546409B2 (en) * | 2009-04-20 | 2013-10-01 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
WO2010138577A1 (en) * | 2009-05-29 | 2010-12-02 | Merck Sharp & Dohme Corp. | Radiolabeled pde10 inhibitors |
CN102647987A (zh) * | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
EP2518071A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EA029473B1 (ru) | 2011-12-15 | 2018-03-30 | Новартис Аг | Применение ингибиторов pi3k для лечения острой и церебральной малярии |
BR112014021935A2 (pt) | 2012-03-05 | 2019-09-24 | Gilead Calistoga Llc | formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona |
TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
HUE034591T2 (en) * | 2012-07-04 | 2018-02-28 | Rhizen Pharmaceuticals S A | Selective PI3K delta inhibitors |
WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
WO2014060432A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
US9737521B2 (en) * | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
TW201522341A (zh) | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
CN104447727B (zh) * | 2013-09-02 | 2018-04-27 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
ES2880999T3 (es) | 2014-05-27 | 2021-11-26 | Rhizen Pharmaceuticals S A | Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas |
MX2016014904A (es) * | 2014-05-27 | 2017-02-28 | Almirall Sa | Sales de adicion de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)e til)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-car bonitrilo. |
BR112016028642A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. |
CU24428B1 (es) | 2014-07-04 | 2019-06-04 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k |
US10550124B2 (en) * | 2015-08-13 | 2020-02-04 | San Diego State University Foundation | Atropisomerism for increased kinase inhibitor selectivity |
HUE063428T2 (hu) | 2016-01-11 | 2024-01-28 | Univ London Queen Mary | PI3K P-DELTA 110 gátlószerei rák kezelésében vírusok bejuttatására történõ alkalmazásra |
WO2017223202A1 (en) | 2016-06-22 | 2017-12-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer |
US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
EP3828184A4 (en) * | 2018-08-21 | 2022-05-04 | Medshine Discovery Inc. | PYRAZOLOPYRIMIDI DERIVATIVES AND USE THEREOF AS A PI3K INHIBITOR |
JP2023521172A (ja) | 2020-04-10 | 2023-05-23 | ジービー005, インコーポレイテッド | キナーゼ阻害剤 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1053063A (es) | 1963-05-18 | |||
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
US3897432A (en) | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
NL7204972A (es) | 1971-04-21 | 1972-10-24 | ||
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
DE2644265C2 (de) | 1976-09-30 | 1983-02-10 | Bayer Ag, 5090 Leverkusen | Chinazoline |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
DE2812635A1 (de) | 1978-03-22 | 1979-09-27 | Bayer Ag | Heterocyclische verbindungen |
JPS55118917A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
JPS55118918A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6017375B2 (ja) | 1979-06-20 | 1985-05-02 | 三菱電機株式会社 | ポリアミド樹脂の製造方法 |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
USRE35862E (en) | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US4925673A (en) | 1986-08-18 | 1990-05-15 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
US5124331A (en) | 1988-03-02 | 1992-06-23 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno[2,3-d]pyrimidine compounds and their pharmaceutical use |
US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
ATE135583T1 (de) | 1991-06-18 | 1996-04-15 | American Home Prod | Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen |
EP0636156B1 (en) | 1992-04-14 | 1997-07-30 | Cornell Research Foundation, Inc. | Dendritic based macromolecules and method of production |
US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
FI951367A (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
WO1996004923A1 (en) | 1994-08-12 | 1996-02-22 | Pro-Neuron, Inc. | Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
JP3233802B2 (ja) | 1994-12-15 | 2001-12-04 | 関西電力株式会社 | 燃焼排ガス中の炭酸ガスと窒素酸化物を除去する方法 |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5948664A (en) | 1996-02-29 | 1999-09-07 | The Regents Of The University Of California | PI 3-kinase polypeptides |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
SK284108B6 (sk) | 1996-05-15 | 2004-09-08 | Pfizer Inc. | 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
ES2199366T3 (es) | 1996-12-31 | 2004-02-16 | Dr. Reddy's Laboratories Ltd. | Compuestos heterociclicos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen y su uso en el tratamiento de diabetes y enfermedades relacionadas. |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
ATE264854T1 (de) * | 1997-02-28 | 2004-05-15 | Pfizer Prod Inc | Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen |
ATE267817T1 (de) | 1997-02-28 | 2004-06-15 | Pfizer Prod Inc | Atropisomere von 3-aryl-4(3h)-chinazolinonen und ihre verwendung als ampa-rezeptor |
ES2245015T3 (es) | 1997-06-09 | 2005-12-16 | Pfizer Products Inc. | Quinazolin-4-onas como antagonistas de ampa. |
AU8280798A (en) | 1997-07-03 | 1999-01-25 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
WO1999034804A1 (en) | 1998-01-08 | 1999-07-15 | The University Of Virginia Patent Foundation | A2a adenosine receptor agonists |
DE69828445D1 (de) | 1998-04-23 | 2005-02-03 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
US6048970A (en) | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
US6100090A (en) | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
US6046049A (en) | 1999-07-19 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p110 delta expression |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
EP1939203B1 (en) | 2000-04-25 | 2014-11-19 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
DE60144277D1 (de) | 2000-04-25 | 2011-05-05 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
JP4782564B2 (ja) | 2002-07-10 | 2011-09-28 | メルク セローノ ソシエテ アノニム | アゾリジノン−ビニル縮合−ベンゼン誘導体 |
GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
CA2400254A1 (en) | 2002-09-19 | 2004-03-19 | University Health Network | Compositions and methods for treating heart disease |
PT2042504E (pt) | 2002-09-30 | 2011-09-07 | Bayer Schering Pharma Ag | Derivados da azolepirimidina fundida |
WO2004052373A1 (en) | 2002-12-06 | 2004-06-24 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
AU2003303231A1 (en) | 2002-12-20 | 2004-07-14 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
SG160211A1 (en) | 2003-04-03 | 2010-04-29 | Semafore Pharmaceuticals Inc | Pi-3 kinase inhibitor prodrugs |
JP2006526614A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 治療用剤としての3−アリールスルファニル及び3−ヘテロアリールスルファニル置換ベンゾ[b]チオフェン |
JP2006526608A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | Pi3k活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド |
EP1644360A1 (en) | 2003-06-05 | 2006-04-12 | Warner-Lambert Company LLC | 3-substituted indoles and derivatives thereof as therapeutic agents |
US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
JP2006526606A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 治療薬としてのシクロアルキル及びヘテロシクロアルキル置換されるベンゾチオフェン |
MXPA05013210A (es) | 2003-06-05 | 2006-03-09 | Warner Lambert Co | Benzo[b]tiofenos cicloalquilsulfanil-sustituidos como agentes terapeuticos. |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
CA2552664A1 (en) * | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
EP1750714A1 (en) | 2004-05-13 | 2007-02-14 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
JP2008500338A (ja) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
US20080287469A1 (en) | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
US20090170834A1 (en) | 2005-12-22 | 2009-07-02 | Prolexys Pharmaceuticals, Inc. | Fused Pyrimidones and Thiopyrimidones, and Uses Thereof |
WO2008064018A1 (en) | 2006-11-13 | 2008-05-29 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US20090131512A1 (en) | 2007-10-31 | 2009-05-21 | Dynavax Technologies Corp. | Inhibition of type I in IFN production |
WO2009088990A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
AU2009313878B2 (en) | 2008-11-13 | 2016-01-07 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CA2745280A1 (en) | 2008-12-04 | 2010-06-10 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
BRPI1012333A2 (pt) | 2009-03-24 | 2016-03-29 | Gilead Calistoga Llc | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso |
US8546409B2 (en) | 2009-04-20 | 2013-10-01 | Gilead Calistoga Llc | Methods of treatment for solid tumors |
CN102647987A (zh) * | 2009-07-21 | 2012-08-22 | 吉里德卡利斯托加公司 | 使用pi3k抑制剂治疗肝脏障碍 |
CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
-
2010
- 2010-03-24 BR BRPI1012333A patent/BRPI1012333A2/pt not_active IP Right Cessation
- 2010-03-24 US US12/731,089 patent/US8440677B2/en not_active Expired - Fee Related
- 2010-03-24 PE PE2011001710A patent/PE20120602A1/es not_active Application Discontinuation
- 2010-03-24 EA EA201171160A patent/EA019499B1/ru not_active IP Right Cessation
- 2010-03-24 EP EP10722454A patent/EP2411391A1/en not_active Withdrawn
- 2010-03-24 NZ NZ595307A patent/NZ595307A/xx not_active IP Right Cessation
- 2010-03-24 CN CN2010800226099A patent/CN102439012A/zh active Pending
- 2010-03-24 AP AP2011005943A patent/AP2011005943A0/xx unknown
- 2010-03-24 WO PCT/US2010/028554 patent/WO2010111432A1/en active Application Filing
- 2010-03-24 AU AU2010229968A patent/AU2010229968A1/en not_active Abandoned
- 2010-03-24 KR KR1020117024913A patent/KR20120002995A/ko not_active Application Discontinuation
- 2010-03-24 MX MX2011009955A patent/MX2011009955A/es active IP Right Grant
- 2010-03-24 JP JP2012502219A patent/JP2012521994A/ja active Pending
- 2010-03-24 CA CA2756347A patent/CA2756347A1/en not_active Abandoned
- 2010-03-24 SG SG2011068822A patent/SG174529A1/en unknown
-
2011
- 2011-09-20 IL IL215251A patent/IL215251A0/en unknown
- 2011-09-23 CL CL2011002359A patent/CL2011002359A1/es unknown
- 2011-10-20 CO CO11140750A patent/CO6450655A2/es not_active Application Discontinuation
- 2011-10-21 EC ECSP11011412 patent/ECSP11011412A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201171160A1 (ru) | 2012-04-30 |
US20100249155A1 (en) | 2010-09-30 |
PE20120602A1 (es) | 2012-05-21 |
CL2011002359A1 (es) | 2012-04-09 |
AP2011005943A0 (en) | 2011-10-31 |
NZ595307A (en) | 2013-11-29 |
IL215251A0 (en) | 2011-12-29 |
EA019499B1 (ru) | 2014-04-30 |
AU2010229968A1 (en) | 2011-10-13 |
ECSP11011412A (es) | 2012-03-30 |
EP2411391A1 (en) | 2012-02-01 |
BRPI1012333A2 (pt) | 2016-03-29 |
CA2756347A1 (en) | 2010-09-30 |
MX2011009955A (es) | 2011-11-18 |
SG174529A1 (en) | 2011-10-28 |
WO2010111432A1 (en) | 2010-09-30 |
CN102439012A (zh) | 2012-05-02 |
US8440677B2 (en) | 2013-05-14 |
KR20120002995A (ko) | 2012-01-09 |
JP2012521994A (ja) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6450655A2 (es) | Atropisómeros de derivados de 2-purinil-3-tolil-quinazolinona y métodos de uso | |
EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
SV2009003299A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
DOP2011000076A (es) | Derivados de heteroaril amidas y su uso como activadores de glucoquinasa | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
NI201100166A (es) | Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa | |
CO6321245A2 (es) | Mimeticos de glucocorticoides metodos para su fabricacion cpomposiciones farmaceuticas y uso de los mismos | |
SV2009003212A (es) | Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct | |
CO6311051A2 (es) | Compuestos de pirimidina, composiciones y metodos de uso | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2008000089A1 (es) | Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios. | |
CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
CO6690816A2 (es) | Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa | |
CR20130464A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
UY30297A1 (es) | Inhibidores de la quinasa c-fms-i | |
SV2011003809A (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
ECSP099071A (es) | Agonistas de ep2 | |
UY32384A (es) | Nuevas bencenosulfonamidas como bloqueadores de canales de calcio | |
AR074379A1 (es) | Inhibidor de triazolotiadiazola de la proteina quinasa c-met | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
EA201101621A1 (ru) | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы | |
AR074214A1 (es) | Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensiblizantes al ca2+ para el tratamiento de la cardiomiopatia hipertrofica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |